Identification of CHCHD2 mutations in patients with Alzheimer's disease, amyotrophic lateral sclerosis and frontotemporal dementia in China

XIXI LIU¹, BIN JIAO¹-³, WEIWEI ZHANG¹, TINGTING XIAO¹, LIHUA HOU¹, CHUZHENG PAN¹, BEISHA TANG¹-⁶ and LU SHEN¹-³,⁷

¹Department of Neurology, Xiangya Hospital; ²Key Laboratory of Hunan Province in Neurodegenerative Disorders, Central South University, Changsha, Hunan 410008; ³National Clinical Research Center for Geriatric Diseases, Changsha, Hunan 410078; ⁴Parkinson's Disease Center of Beijing Institute for Brain Disorders, Beijing 100069; ⁵Collaborative Innovation Center for Brain Science, Shanghai 200032; ⁶Collaborative Innovation Center for Genetics and Development, Shanghai 200433; ⁷Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan, Changsha, Hunan 410008, P.R. China

Received December 1, 2017; Accepted April 26, 2018

DOI: 10.3892/mmr.2018.8962

Abstract. Recently, the coiled-coil-helix-coiled-coil-helix domain 2 (CHCHD2) gene was identified as a possible causative gene for Parkinson's disease (PD). Three other neurodegenerative diseases, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), share significant overlaps with PD in clinical phenotypes, pathological features and genetic heredities, and it is still unclear whether CHCHD2 variants could explain these three diseases. The present study screened all exons of the CHCHD2 gene in a total of 780 patients (511 AD, 181 ALS and 88 FTD) and 500 healthy controls from the Chinese Han population. Two missense variants, 5C>T (Pro2Leu) and 238A>G (Ile80Val), were identified in five unrelated patients with AD while no mutations were observed in patients with ALS or FTD. These mutations have been reported as low-frequency variants in the ExAC database with frequencies of 0.0075 and 0.000025. Pro2Leu, however, was also detected in controls and was confirmed to have no significant association with the risk for AD; Ile80Val was not detected in any normal controls, suggesting that the CHCHD2 gene may be associated with AD in the Chinese Han population.

Introduction

The coiled-coil-helix-coiled-coil-helix domain (CHCHD)-containing proteins are small mitochondrial proteins with important functions. Mutations of CHCHD genes have been identified to be associated with various human neurodegenerative diseases (1). CHCHD10, which is a CHCHD protein, was identified to be associated with amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease (AD) in Chinese population (2,3). Recently, the CHCHD2 gene was identified as a possible causative gene for Parkinson's disease (PD). A missense mutation (Thr61Ile) in this gene was first detected in a multigenerational Japanese family with autosomal dominant PD (ADPD) (4). Several subsequent efforts have been made to confirm the association between the CHCHD2 gene and PD in other ethnicities, including European and Chinese populations. Jansen et al (5) reported three novel putative pathogenic variants (Ala32Thr, Pro34Leu, and Ile80Val) in patients with PD from a western European population; another study identified a heterozygous variant (182C>T; Thr61Ile) in an ADPD pedigree in a Chinese population (6). The CHCHD2 gene is located on chromosome 7p11.2 and contains four exons encoding 151 amino acids with a predicted N-terminal mitochondrial targeting sequence (7). The CHCHD2 protein is a small mitochondrial protein that serves as one of the negative regulators of mitochondria-mediated apoptosis. The knockdown of CHCHD2 promoted a significant increase in nuclear fragmentation and in phosphatidylserine exposure, both of which are hallmarks of apoptosis (8).

Neurodegenerative disorders are conditions that have yet to be fully elucidated. Nevertheless, different types of neurodegenerative disorders are closely related, including the four major types: PD, AD, ALS and FTD. Although they are different diseases with distinct features, they manifest overlapping clinical phenotypes, pathologic features and genetic backgrounds. For instance, the PD-related genetic variant rs76904798 of leucine-rich repeat kinase 2 (LRRK2) is found to be a common genetic risk variant for late-onset AD (LOAD) susceptibility in a northern Han Chinese people (9). Expansions in the C9orf72 gene are most frequently associated...
with ALS-FTD and can be combined with symmetrical Parkinsonism; FTD in patients with mutations in the gene that encodes microtubule-associated protein tau (MAPT) can also manifest as symmetrical Parkinsonism (10).

In addition, mitochondrial dysfunction has been described in neurodegenerative disorders. In addition to CHCHD2, the proteins that are associated with familial PD-PHENOMENON-induced putative kinase 1 (PINK1), DJ-1, alpha-synuclein and LRRK2-are either mitochondrial proteins or associated with mitochondria, and all interface with the pathways of oxidative stress and free radical damage (11). In AD, aggregation of β-amyloid (Aβ) is central to initiating AD pathogenesis. In the brain and in isolated mitochondria, exposure to Aβ inhibits key mitochondrial enzymes (12). As mentioned above, mutations of CHCHD10 are associated with ALS and/or FTD, AD.

In this study, to confirm the potential role of CHCHD2 in these three diseases, we assessed the prevalence of CHCHD2 mutations in AD, ALS and FTD patients.

Patients and methods

Patients. This study recruited a total of 511 AD patients (436 sporadic AD and 75 probands from FAD families, mean age at onset was 66.2±5.5 years, male: 44.0%), 181 ALS patients (166 sporadic ALS and 15 familial ALS, mean age at onset was 48.1±13.4 years, male: 67.9%) and 88 FTD patients (77 sporadic FTD and 11 familial FTD, mean age at onset was 53.3±9.7 years, male: 42.0%) from mainland China in 2014 to 2016. The diagnoses of probable or possible AD according to the NINCDS-ADRDA criteria were made by 2 or more experienced neurologists in Xiangya Hospital. The diagnoses of ALS were made according to the El Escorial revised criteria. The diagnoses of FTD met the Lund-Manchester criteria (13-15). Neuroradiological examinations for example MRI, was assessed with patients diagnosed as probable or possible AD and FTD in this study. We have excluded AD, FTD and ALS patients carrying disease-causing gene like PSEN1, PSEN2, APP, MAPT, GRN, C9orf72, TREM2, CHCHD10, SOD1, TARDBP, FUS (3,16-20). Additionally, the APOE genotype was available for all AD patients. A total of 500 healthy unrelated age-matched Chinese individuals without a history of neurodegenerative disease were recruited from the Xiangya Wellness Center as a control group. Written informed consent for participation in the study was obtained from all subjects. For patients who can understand our study, we asked for the consent of the patients, and for severe patients, we sought the consent of the patient's guardian or immediate family members. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Expert Committee of Xiangya Hospital of Central South University in China.

DNA isolation and genotyping methods. Genomic DNA was extracted from peripheral blood leukocytes from all patients and controls. The quality and quantity of DNA were assessed with a fluorometer. All DNA samples were diluted to 50 ng/ml. Polymerase chain reaction (PCR) was performed on the exonic regions of CHCHD2. The CHCHD2 sequencing (exons 1-4) was amplified using primers designed according to the GenBank entries (data not shown). Each PCR product was sequenced using forward and reverse primers identical to the ones used in PCR with BigDye terminator v3.1 sequencing chemistry on an ABI 3730xl DNA analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The DNA sequences were analyzed using Seqencher software.

Statistical analysis. When a mutation was detected, we first confirmed whether it was a novel or rare (MAF<1%) mutation by comparison with sequences in the ExAC (exac.broadinstitute.org/) and 1000 Genomes Project databases (www.1000genomes.org/) and with direct sequencing of healthy controls. We then use bioinformatics prediction tools like Mutation Taster (mutationtaster.org), REVEL (sites.google.com/site/revelgenomics/downloads), CADD (cadd.gs.washington.edu/download) to predict the pathogenicity of the mutation. Statistical analysis of clinical data was performed using IBM SPSS 19.0 (IBM Corp., Armonk, NY, USA). To compare the differences among the patients and controls, the Fisher's exact test was used. The threshold of statistical significance was set at P<0.05. Descriptive statistics were expressed as the mean ± the standard deviation.

Results

The demographic features of 511 AD, 181 ALS and 88 FTD cases and 500 controls are shown in Table I. The Clinical features and APOE genotype of the carriers is presented in Table II.

Two rare heterozygous variants of CHCHD2, 5C>T (Pro2Leu) and 238A>G (Ile80Val), were found in five of 311 AD patients.

The variant Pro2Leu was identified in four patients with typical symptoms of cognitive impairment; three of them had sporadic AD, and one had a family history of AD. The patient with a family history developed progressive memory impairment at the age of 67. At the onset, she easily forgot what she had just done. Then, she began to forget her relatives’ names and could not find her way home. Finally, multiple cognitive domains were impaired. Her Mini-Mental State Examination (MMSE) score was 5 of 30 points; her Montreal cognitive assessment scale (MoCA) score was 4 of 30 points. Her mother also had symptoms of memory loss, according to the recollection of the patient’s family. One of the proband’s sisters (Fig. 1A, M6937: II3) who had similar symptoms also carried the same variant. Unfortunately, DNA samples from other family members were unavailable for genetic analysis. This variant showed a frequency of 0.007475 in the ExAC database. We also detected this variant with equal frequency in our control group (Table III), which indicated that there was no significant association between Pro2Leu and the risk for AD in our cohort.

The variant Ile80Val was identified in a male patient who developed progressive memory loss at the age of 67. A year later, he had a change of personality. Specifically, he became less talkative and more aggressive than he used to be. The patient went to see a doctor at the age of 70; his MMSE score was 5 of 30 points, and his MoCA score was 0 of 30 points. His mother began suffering from memory loss at the age of 81; two years later, she lost the ability to live independently and died because of pulmonary infection. One of the proband’s younger sister (Fig. 1A, M31801: II-3) and his two sons (III-1 and III-2)
agreed to participate in our study. We performed cognitive evaluation and genetic analysis of these three members, it turned out that one of his son (Ⅲ‑2) carried this variant while others did not (all of them are cognitively normal). We will continue to monitor whether he develops any symptoms of AD. This variant showed a frequency of 0.000025 in ExAC and was not detected in data from the 1000 Genomes Project and was also absent in our 500 healthy control individuals. The variant sequences in patients and references are presented in Fig. 1B.

Both of these two variants were highly conserved among the primary species (Fig. 1C) and were predicted to be detrimental based on the Mutation Taster. The variant 5C>T (Pro2Leu) was predicted to be the 1% most deleterious and the variant 238A>G (Ile80Val) to be the 10% most deleterious according to CADD. However, these two variants are less likely to cause disease in REVEL prediction (Table III).

No CHCHD2 variant was detected in patients with ALS or FTD. In our 181 ALS and 88 FTD samples, Sanger sequencing ruled out coding mutations in CHCHD2, suggesting that CHCHD2 might not be a risk gene in these two diseases.

Discussion

CHCHD2 co-expresses with other genes of the oxidative phosphorylation pathway, and the CHCHD2 protein serves as a transcription factor to activate the oxygen response element (ORE) in the COX4I2 gene (21). Funayama et al (4) first identified a missense mutation (Thr61Ile) of CHCHD2 in a multigenerational Japanese family with ADPD. Subsequently, they found two more mutations, one missense mutation (434G>A, Arg145Gln) and one splice‑site mutation (300+5G>A), in two other families. And none of these three mutations was noted in the 559 unaffected Japanese controls (4). Of these mutations, only the Thr61Ile mutation was confirmed to cosegregate in two independent families with ADPD (22). In addition to PD, recent studies have reported that CHCHD2 expression was increased in neural stem cell lines derived from a patient with Huntington's disease, and gene variants of CHCHD2 were also detected in patients with Lewy body disease (LBD) (23,24). Based on these observations, the CHCHD2 gene might be involved in various neurodegenerative diseases.

In this study, we detected two single nucleotide variants of CHCHD2 (Pro2Leu and Ile80 Val) in five AD patients. All of these five patients had typical symptoms of AD. Pro2Leu was confirmed to have different frequencies in patients with sporadic PD and controls by Funayama et al (4) and Shi et al (6). Another similar research that may be carried out at the same time with this study found four variants of CHCHD2 gene in AD and FTD patients and one of them is Pro2Leu (25). However, in terms of our results, this variant might not be significantly associated with AD. Ile80Val

Table I. Demographic information of patients and control groups.

<table>
<thead>
<tr>
<th>Variable</th>
<th>AD</th>
<th>ALS</th>
<th>FTD</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases, n</td>
<td>511</td>
<td>181</td>
<td>88</td>
<td>500</td>
</tr>
<tr>
<td>No. of male cases, n (%)</td>
<td>225 (44.0)</td>
<td>123 (68.0)</td>
<td>37 (42.0)</td>
<td>253 (50.6)</td>
</tr>
<tr>
<td>Age at onset, years</td>
<td>66.2±5.5</td>
<td>48.1±13.4</td>
<td>53.3±9.7</td>
<td>-</td>
</tr>
<tr>
<td>Age at examination, years</td>
<td>70.0±5.7</td>
<td>50.8±1.3</td>
<td>58.5±11.5</td>
<td>69.3±6.1</td>
</tr>
<tr>
<td>MMSE score</td>
<td>18.1±7.78</td>
<td>-</td>
<td>16.3±9.45</td>
<td>28.7±1.4</td>
</tr>
</tbody>
</table>

Data are presented as the mean ± standard deviation. MMSE, Mini‑Mental State Examination; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; -, data not available.

Table II. Clinical features of Alzheimer's disease patients carrying variants of the CHCHD2 gene.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>M6937</th>
<th>M14200</th>
<th>M14851</th>
<th>M24736</th>
<th>M31801</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>Family history</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
</tr>
<tr>
<td>Age at onset (years)</td>
<td>67</td>
<td>60</td>
<td>82</td>
<td>53</td>
<td>67</td>
</tr>
<tr>
<td>Age at examination (years)</td>
<td>79</td>
<td>64</td>
<td>91</td>
<td>58</td>
<td>70</td>
</tr>
<tr>
<td>MMSE</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>22</td>
<td>5</td>
</tr>
<tr>
<td>MoCA</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>9</td>
<td>0</td>
</tr>
<tr>
<td>Variant</td>
<td>5C&gt;T(Pro2Leu)</td>
<td>5C&gt;T(Pro2Leu)</td>
<td>5C&gt;T(Pro2Leu)</td>
<td>5C&gt;T(Pro2Leu)</td>
<td>238A&gt;G(Ile80Val)</td>
</tr>
</tbody>
</table>

CHCHD2, coiled-coil-helix-coiled-helix domain 2; Y, yes; N, no; MMSE, Mini‑Mental State Examination; MoCA, Montreal cognitive assessment scale; APOE, apolipoprotein E.
was first identified in a PD patient in a western European population (5). According to the ExAC database and the 1000 Genomes Project, this variant has not been previously detected in an East Asian population. Ile80Val is located in a transmembrane domain and was predicted to be detrimental based on the Mutation Taster and CADD (8). Nonetheless, the REVEL predicted a score of 0.009 for this mutation, which might not cause disease. Considering the reasons given above, CHCHD2 is not likely to be a causative gene of AD in the Chinese population but might be associated with AD and AD might share a common pathway with PD in mitochondrial dysfunction. However, the pathogenicity of this variant
remains uncertain. Further functional experiments are needed to investigate how CHCHD2 plays a role in AD and PD.

No mutation of CHCHD2 was observed in either the 181 ALS or the 88 FTD patients. There are several possible explanations for these negative results. The first possibility is that CHCHD2 might not be associated with these two diseases in the Chinese population, although many pathogenic gene mutations can be detected in ALS, FTD and PD. Another explanation for these results is that the CHCHD2 gene might have genetic heterogeneity in different ethnic groups and since some CHCHD2 gene mutations are very rare, more samples should be included to provide more solid evidence.

Rare coding variants play major roles in disease causation and might contribute to the missing heritability from genome-wide association studies. In this study, to find out whether these mutations play a role in the disease, we use bioinformatics prediction tools to predict the pathogenicity of the mutation and compared its frequency with healthy control. However, the present study has several limitations. Firstly, association study requires a larger sample size to detect rare variants with modest effect sizes with high statistical power. Secondly, bioinformatics prediction tools rely on pathogenicity assertions from existing databases, which might be inaccurate and incomplete.

In general, this study identified a novel mutation of the CHCHD2 gene in Chinese AD patients, while no mutation of CHCHD2 was observed in either ALS or FTD patients, suggesting that the CHCHD2 gene might be associated with AD in the Chinese Han population. Further screening should be conducted in a large number of samples and in different ethnicities and further functional experiments are needed.

Acknowledgements

Not applicable.

Funding

The present study was supported through the National Natural Science Foundation of China (grant nos. 81671075 and 81701134).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

XL, BJ, LS and BT designed the study. XL, WZ, TX, LH, CP and BT conducted the experiments, and analyzed and interpreted the data. XL and LS wrote the manuscript. BT and LS supervised the study. BJ and LS provided financial support.

Ethics approval and consent to participate

The present study was conducted in accordance with the Declaration of Helsinki and was approved by the Expert Committee of Xiangya Hospital of Central South University in China ( Hunan, China; ref. no. 201603198). Written informed consent for participation in the study was obtained from all subjects; consent was obtained from the patient's guardian or immediate family member for those without the capacity to consent.

Consent for publication

Written informed consent was obtained from all subjects; consent was obtained from the patient's guardian or immediate family member for those without the capacity to consent.

Competing interests

The authors declare that they have no competing interests.

References